Literature DB >> 15470036

Restriction of de novo nucleotide biosynthesis interferes with clonal expansion and differentiation into effector and memory CD8 T cells.

Laurence Quéméneur1, Laurent Beloeil, Marie-Cécile Michallet, Georgi Angelov, Martine Tomkowiak, Jean-Pierre Revillard, Jacqueline Marvel.   

Abstract

Nucleotide synthesis inhibitors are currently used in neoplastic diseases or as immunosuppressive agents for the prevention of acute rejection in organ transplantation and the treatment of autoimmune disorders. We have previously described that these inhibitors interfere with proliferation and survival of primary T cells in vitro. However, the precise effects of nucleotide restriction on effector and memory functions have not been elucidated. In this study, we investigated the impact of nucleotide synthesis inhibition on CD8 T cell differentiation by using TCR transgenic mice (F5) specific for the influenza virus nucleoprotein 68 peptide presented on the H-2Db molecule. Our results show that methotrexate and 5-fluorouracil prevent the acquisition of effector functions, such as IFN-gamma, granzyme B expression, and cytotoxic function following antigenic stimulation of naive cells. Surprisingly, in the presence of mycophenolate mofetil, activated F5 cells are still able to produce granzyme B and to kill target cells but to a lesser extent compared with control. All three inhibitors interfere with the differentiation of naive cells into memory CD8 T cells. In contrast, the drugs are unable to inhibit the development of improved cytotoxic functions displayed by memory CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470036     DOI: 10.4049/jimmunol.173.8.4945

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Pyrophosphate interactions at the transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2010-06-30       Impact factor: 15.419

2.  Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Gary B Evans; Keith Clinch; Douglas R Crump; Lawrence D Harris; Richard F G Fröhlich; Peter C Tyler; Keith Z Hazleton; María B Cassera; Vern L Schramm
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

3.  MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.

Authors:  Ayaka Sugiura; Gabriela Andrejeva; Kelsey Voss; Darren R Heintzman; Xincheng Xu; Matthew Z Madden; Xiang Ye; Katherine L Beier; Nowrin U Chowdhury; Melissa M Wolf; Arissa C Young; Dalton L Greenwood; Allison E Sewell; Shailesh K Shahi; Samantha N Freedman; Alanna M Cameron; Patrik Foerch; Tim Bourne; Juan C Garcia-Canaveras; John Karijolich; Dawn C Newcomb; Ashutosh K Mangalam; Joshua D Rabinowitz; Jeffrey C Rathmell
Journal:  Immunity       Date:  2021-11-11       Impact factor: 31.745

4.  Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases.

Authors:  Maria De Santis; Francesca Motta; Natasa Isailovic; Massimo Clementi; Elena Criscuolo; Nicola Clementi; Antonio Tonutti; Stefano Rodolfi; Elisa Barone; Francesca Colapietro; Angela Ceribelli; Matteo Vecellio; Nicoletta Luciano; Giacomo Guidelli; Marta Caprioli; Clara Rezk; Lorenzo Canziani; Elena Azzolini; Luca Germagnoli; Nicasio Mancini; Ana Lleo; Carlo Selmi
Journal:  Vaccines (Basel)       Date:  2022-05-18

5.  Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Minkui Luo; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2009-04-08       Impact factor: 15.419

6.  Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.

Authors:  Bradley N Mills; Kelli A Connolly; Jian Ye; Joseph D Murphy; Taylor P Uccello; Booyeon J Han; Tony Zhao; Michael G Drage; Aditi Murthy; Haoming Qiu; Ankit Patel; Nathania M Figueroa; Carl J Johnston; Peter A Prieto; Nejat K Egilmez; Brian A Belt; Edith M Lord; David C Linehan; Scott A Gerber
Journal:  Cell Rep       Date:  2019-10-08       Impact factor: 9.423

Review 7.  Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence.

Authors:  Koosha Paydary; Natalie Reizine; Daniel V T Catenacci
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

8.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Authors:  Kohei Shitara; Eric Van Cutsem; Yung-Jue Bang; Charles Fuchs; Lucjan Wyrwicz; Keun-Wook Lee; Iveta Kudaba; Marcelo Garrido; Hyun Cheol Chung; Jeeyun Lee; Hugo Raul Castro; Wasat Mansoor; Maria Ignez Braghiroli; Nina Karaseva; Christian Caglevic; Luis Villanueva; Eray Goekkurt; Hironaga Satake; Peter Enzinger; Maria Alsina; Al Benson; Joseph Chao; Andrew H Ko; Zev A Wainberg; Uma Kher; Sukrut Shah; S Peter Kang; Josep Tabernero
Journal:  JAMA Oncol       Date:  2020-10-01       Impact factor: 31.777

9.  Targeting Future Pandemics, a Case for De Novo Purine Synthesis and Basic Research.

Authors:  Randall C Mazzarino
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

10.  In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes.

Authors:  Maciej Guzera; Lidia Szulc-Dąbrowska; Anna Cywińska; Joy Archer; Anna Winnicka
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.